



NDA 22-013

Connetics Corporation
Attention: Michael S. Eison, Ph.D.
Vice President, Regulatory Affairs
3160 Porter Drive
Palo Alto, California 94304

Dear Dr. Eison:

Please refer to your new drug application (NDA) dated March 14, 2006, received March 16, 2006, submitted pursuant to section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act for Olux-E (clobetasol propionate) Foam, 0.05%.

We acknowledge receipt of your submissions dated May 11, June 9, July 14 (2) and 20, August 31, September 5, 11 and 22, October 5, 19, 20 and 30, November 8, 10, 16, 21, and 28, December 18 and 20, 2006, and January 9, 2007.

This new drug application provides for the use of Olux-E (clobetasol propionate) Foam, 0.05% for the treatment of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.

We have completed our review of this application, as amended. It is approved, effective on the date of this letter, for use as recommended in the agreed-upon labeling text.

The final printed labeling (FPL) must be identical to the enclosed labeling (text for the package insert). Marketing the product with FPL that is not identical to the approved labeling text may render the product misbranded and an unapproved new drug.

Please submit an electronic version of the FPL according to the guidance for industry titled *Providing Regulatory Submissions in Electronic Format - NDA*. Alternatively, you may submit 20 paper copies of the FPL as soon as it is available but no more than 30 days after it is printed. Individually mount 15 of the copies on heavy-weight paper or similar material. For administrative purposes, designate this submission "**FPL for approved NDA 22-013.**" Approval of this submission by FDA is not required before the labeling is used.

Within 21 days of the date of this letter, submit content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format, as described at <http://www.fda.gov/oc/datacouncil/spl.html>, that is identical in content to the enclosed labeling text. Upon receipt and verification, we will transmit that version to the National Library of Medicine for public dissemination.

All applications for new active ingredients, new dosage forms, new indications, new routes of administration, and new dosing regimens are required to contain an assessment of the safety and effectiveness of the product in pediatric patients unless this requirement is waived or deferred. We note that you have fulfilled the pediatric study requirement for this application.

We remind you of your postmarketing study commitments in your submission dated September 11, 2006. These commitments are listed below.

1. Dermal Carcinogenicity Study

Protocol Submission: by 01/09
Study Start: by 09/09
Final Report Submission: by 03/13

2. Photocarcinogenicity Study

Protocol Submission: by 01/09
Study Start: by 09/09
Final Report Submission: by 03/12

Submit clinical protocols to your IND for this product. Submit nonclinical and chemistry, manufacturing, and controls protocols and all study final reports to this NDA. In addition, under 21 CFR 314.81(b)(2)(vii) and 314.81(b)(2)(viii), you should include a status summary of each commitment in your annual report to this NDA. The status summary should include expected summary completion and final report submission dates, any changes in plans since the last annual report, and, for clinical studies, number of patients entered into each study. All submissions, including supplements, relating to these postmarketing study commitments must be prominently labeled **“Postmarketing Study Commitment Protocol”**, **“Postmarketing Study Commitment Final Report”**, or **“Postmarketing Study Commitment Correspondence.”**

In addition, submit three copies of the introductory promotional materials that you propose to use for this product. Submit all proposed materials in draft or mock-up form, not final print. Send one copy to this division and two copies of both the promotional materials and the package insert directly to:

Food and Drug Administration
Center for Drug Evaluation and Research
Division of Drug Marketing, Advertising, and Communications
5901-B Ammendale Road
Beltsville, MD 20705-1266

Please submit one market package of the drug product when it is available.

We have not completed validation of the regulatory methods. However, we expect your continued cooperation to resolve any problems that may be identified.

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

NDA 22-013

Page 3

If you have any questions, call Margo Owens, Regulatory Project Manager, at (301) 796-2110.

Sincerely,

{See appended electronic signature page}

Susan Walker, M.D.
Director
Division of Dermatology and Dental Products
Office of Drug Evaluation III
Center for Drug Evaluation and Research

Enclosure

**This is a representation of an electronic record that was signed electronically and
this page is the manifestation of the electronic signature.**

/s/

Susan Walker
1/12/2007 11:00:55 AM
Approved